

MEDIA UPDATE

Novartis, Voyager Therapeutics reach license option agreement for next-generation gene therapy vectors for neurological diseases

- *Novartis gains target-specific access to next-generation AAV capsids that could be used for three diseases of the central nervous system, with options for two additional targets*
- *Agreement builds on previous Novartis success using emerging technologies to develop first-in-class gene therapies for neurological disorders*
- *Capsids from Voyager's TRACER platform may help deliver therapies to previously intractable regions of the brain, potentially overcoming barriers that have hindered development of gene therapies for neurological diseases to date*

Basel, March 8, 2022 — Novartis today announced a license option agreement with Voyager Therapeutics, a gene therapy company focused on next-generation adeno-associated virus (AAV) technologies, for three capsids to use in potential gene therapies for neurological diseases, with options to access capsids for two other targets.

A leader in gene therapy with a strong commitment to developing treatments for diseases of the central nervous system, Novartis seeks to apply its expertise and recent learnings to neurological diseases that manifest in deep brain regions where commonly used vectors have not been shown to effectively target and penetrate.

“The challenge of biodistribution of AAV gene therapies to target cell types in the brain is longstanding, but we refuse to believe it is insurmountable,” said Jay Bradner, President of the Novartis Institutes for BioMedical Research (NIBR). “We see the potential of Voyager’s innovative platform to imagine new types of therapeutics for life-threatening CNS diseases.”

Data suggest that AAV capsids emerging from Voyager’s proprietary TRACER platform (which stands for Tropism Redirection of AAV by Cell type-specific Expression of RNA) may show broad and improved distribution to neurons in the cortex and deeper brain regions.

“We have a robust pipeline of gene therapy programs to target diseases of the central nervous system – a number of them requiring enhanced delivery vectors that reach cells in multiple brain regions, which has not been possible with technologies used to date,” said Bob Baloh, Head of Neuroscience at NIBR. “We look forward to evaluating these capsids from Voyager’s TRACER platform, which hopefully will enable us to bring new therapeutic options to patients with devastating neurological conditions.”

Under the terms of the agreement, Novartis will have the right to evaluate novel capsids from Voyager's TRACER platform and to exercise options to license capsids for exclusive use in Novartis' development of AAV gene therapies directed to three targets. Novartis has the right to license capsids for two additional disease targets under the same terms. Voyager will receive an upfront payment, with additional payments for each exercised option, as well as future milestones and sales-based royalties.

About Novartis

This is a standard statement, see below, containing information about the company. It is updated every quarter and must be included exactly as given. You may also have a standard statement specific to your Business Franchise or Business Unit that can be added before the corporate statement as a separate paragraph.

Novartis is reimagining medicine to improve and extend people's lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world's top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 108,000 people of more than 140 nationalities work at Novartis around the world. Find out more at <https://www.novartis.com>.

Novartis is on Twitter. Sign up to follow @Novartis at <https://twitter.com/novartisnews>
For Novartis multimedia content, please visit <https://www.novartis.com/news/media-library>
For questions about the site or required registration, please contact media.relations@novartis.com

###

Novartis Media Relations

E-mail: media.relations@novartis.com

Amy Wolf
Novartis External Communications
+41 79 576 0723
amy.wolf@novartis.com

Mary Carmichael
NIBR Communications
+1 617 413 3543 (mobile)
mary.carmichael@novartis.com

Novartis Investor Relations

Central investor relations line: +41 61 324 7944

E-mail: investor.relations@novartis.com

Central		North America	
Samir Shah	+41 61 324 7944	Sloan Simpson	+1 862 345 4440
Nicole Zinsli-Somm	+41 61 324 3809	Alina Levchuk	+1 862 778 3372
Isabella Zinck	+41 61 324 7188	Parag Mahanti	+1 973-876-4912